J9046 Inj, bortezomib, dr. reddy'sInjection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg
Status E: excluded from the PFS by regulation.
45 of 45 payer prior-auth lists that name J9046 require prior authorization or set conditions: Aetna, Blue Cross Blue Shield of Arizona (AZ Blue), Blue Shield of California Promise Health Plan, CarePlus Health Plans, Cigna, HealthSpring, Humana, Molina Complete Care (Virginia), Molina Healthcare of California, Molina Healthcare of Idaho, Molina Healthcare of Illinois, Molina Healthcare of Iowa, Molina Healthcare of Michigan, Molina Healthcare of Mississippi, Molina Healthcare of Ohio, Molina Healthcare of Texas, Molina Healthcare of Utah, Passport by Molina Healthcare (Kentucky), UnitedHealthcare, UnitedHealthcare Community Plan.
J9046 appears in 33 coverage policies from Aetna, BlueCross BlueShield of South Carolina, Centene, Premera Blue Cross.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Antiemetic Therapy (0724) | listed, no stance | Jul 17, 2026 | payer document |
| Aetna | Belantamab Mafodotin-blmf (Blenrep) (0981) Ixazomib, Lenalidomide, Pomalidomide | listed, no stance | Feb 6, 2026 | payer document |
| Aetna | Bendamustine Products (0875) | listed, no stance | Sep 15, 2026 | payer document |
| Aetna | Bortezomib Products (0675) | covered if criteria are met | Feb 17, 2026 | payer document |
| Aetna | Carfilzomib (Kyprolis) (0845) | listed, no stance | Mar 2, 2026 | payer document |
| Aetna | Ciltacabtagene Autoleucel (Carvykti) (1007) | listed, no stance | Mar 13, 2026 | payer document |
| Aetna | Daratumumab (Darzalex) and Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) (0904) Pomalidomide, lenalidomide, thalidomide, Selinexor, Venetoclax | listed, no stance | Jun 8, 2026 | payer document |
| Aetna | Elotuzumab (Empliciti) (0899) | listed, no stance | Mar 2, 2026 | payer document |
| Aetna | Elranatamab-bcmm (Elrexfio) (1040) | listed, no stance | Dec 10, 2025 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Hodgkin's Disease (0495) | listed, no stance (range J9000-J9999) | Jul 2, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Multiple Myeloma (0497) | listed, no stance (range J9000-J9999) | Aug 5, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors (0496) | listed, no stance (range J9000-J9999) | Aug 6, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (0626) | listed, no stance (range J9000-J9999) | Sep 18, 2026 | payer document |
| Aetna | Hematopoietic Colony-Stimulating Factors (CSFs) (0055) | listed, no stance | Jul 16, 2026 | payer document |
| Aetna | Infusion Pumps (0161) | covered if criteria are met (range J9000-J9999) | Mar 31, 2026 | payer document |
| Aetna | Injectable Medications (0020) | listed, no stance (range J9000-J9999) | Mar 5, 2026 | payer document |
| Aetna | Isatuximab-irfc (Sarclisa) (0969) | listed, no stance | Mar 2, 2026 | payer document |
| Aetna | Linvoseltamab-gcpt (Lynozyfic) (1089) | listed, no stance | Jul 17, 2026 | payer document |
| Aetna | Margetuximab-cmkb (Margenza) (0985) | listed, no stance (range J9000-J9999) | May 27, 2026 | payer document |
| Aetna | Negative Pressure Wound Therapy (0334) | listed, no stance (range J9000-J9999) | Jun 8, 2026 | payer document |
| Aetna | Pertuzumab Products (0973) | listed, no stance (range J9000-J9999) | Apr 27, 2026 | payer document |
| Aetna | Phototherapy and Photochemotherapy (PUVA) for Skin Conditions (0205) | listed, no stance (range J9000-J9999) | May 18, 2026 | payer document |
| Aetna | Radium Ra 223 Dichloride (Xofigo) (0874) | listed, no stance | Dec 22, 2025 | payer document |
| Aetna | Revakinagene Taroretcel-lwey (Encelto) (1079) | listed, no stance (range J8501-J9999) | Oct 5, 2026 | payer document |
| Aetna | Talquetamab-tgvs (Talvey) (1042) | listed, no stance | Oct 9, 2026 | payer document |
| Aetna | Teclistamab-cqyv (Tecvayli) (1018) | listed, no stance | Jun 8, 2026 | payer document |
| Aetna | Tumor Chemoresistance Assays (0758) | listed, no stance (range J9000-J9999) | Dec 2, 2025 | payer document |
| Aetna | Tumor Chemosensitivity Assays (0245) | listed, no stance (range J9000-J9999) | Apr 13, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Cell Transplantation for Breast Cancer (CAM 80127) | listed, no stance (range J9000-J9999) | Jul 1, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults (CAM 80124) | unproven / investigational (range J9000-J9999) | Jul 1, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome (CAM 80117) | listed, no stance (range J9000-J9999) | Jan 1, 2026 | payer document |
| Centene | Bortezomib (Boruzu, Velcade) (CP.PHAR.410) | covered if criteria are met | Feb 1, 2026 | payer document |
| Premera Blue Cross | Miscellaneous Oncology Drugs (5.01.540) | listed, no stance | Oct 1, 2026 | payer document |
Prior authorization required or conditional in VA, WA.
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.